Hideto Kameda

6.6k total citations
196 papers, 4.3k citations indexed

About

Hideto Kameda is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Hideto Kameda has authored 196 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 147 papers in Rheumatology, 63 papers in Hematology and 50 papers in Immunology. Recurrent topics in Hideto Kameda's work include Rheumatoid Arthritis Research and Therapies (109 papers), Autoimmune and Inflammatory Disorders Research (57 papers) and Systemic Lupus Erythematosus Research (52 papers). Hideto Kameda is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (109 papers), Autoimmune and Inflammatory Disorders Research (57 papers) and Systemic Lupus Erythematosus Research (52 papers). Hideto Kameda collaborates with scholars based in Japan, United States and Germany. Hideto Kameda's co-authors include Tsutomu Takeuchi, Yoshiya Tanaka, Kazuyoshi Saito, Koichi Amano, Hayato Nagasawa, Naoya Sekiguchi, Yuko Kaneko, Kouichi Amano, Hisashi Yamanaka and Masao Nawata and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and Molecular and Cellular Biology.

In The Last Decade

Hideto Kameda

186 papers receiving 4.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hideto Kameda Japan 38 2.6k 1.2k 1.2k 675 631 196 4.3k
Raimón Sanmartí Spain 40 3.6k 1.4× 1.3k 1.1× 1.6k 1.4× 385 0.6× 416 0.7× 263 5.3k
Xavier Le Loët France 42 3.3k 1.3× 1.3k 1.1× 1.4k 1.2× 371 0.5× 644 1.0× 198 5.4k
Elliot Chartash United States 23 3.0k 1.1× 1.5k 1.3× 1.4k 1.2× 259 0.4× 601 1.0× 49 4.7k
Andrea Rubbert‐Roth Germany 33 3.3k 1.3× 1.5k 1.3× 1.7k 1.4× 277 0.4× 885 1.4× 123 5.1k
A. Mékinian France 38 1.4k 0.5× 626 0.5× 1.1k 1.0× 418 0.6× 552 0.9× 231 4.4k
Pierre Geborek Sweden 33 2.5k 0.9× 889 0.8× 1.1k 1.0× 414 0.6× 509 0.8× 73 3.6k
Alejandro Balsa Spain 43 3.3k 1.2× 920 0.8× 2.4k 2.0× 495 0.7× 596 0.9× 285 6.1k
Olivier Vittecoq France 36 2.0k 0.8× 547 0.5× 776 0.7× 465 0.7× 302 0.5× 165 3.5k
Eva Baecklund Sweden 33 2.4k 0.9× 816 0.7× 934 0.8× 715 1.1× 1.1k 1.8× 75 4.9k
Emilio Martín Mola Spain 14 2.5k 1.0× 1.2k 1.0× 792 0.7× 584 0.9× 524 0.8× 32 3.7k

Countries citing papers authored by Hideto Kameda

Since Specialization
Citations

This map shows the geographic impact of Hideto Kameda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideto Kameda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideto Kameda more than expected).

Fields of papers citing papers by Hideto Kameda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hideto Kameda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideto Kameda. The network helps show where Hideto Kameda may publish in the future.

Co-authorship network of co-authors of Hideto Kameda

This figure shows the co-authorship network connecting the top 25 collaborators of Hideto Kameda. A scholar is included among the top collaborators of Hideto Kameda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hideto Kameda. Hideto Kameda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Harigai, Masayoshi, Yuko Kaneko, Eiichi Tanaka, et al.. (2025). 2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis: Secondary publication. Modern Rheumatology. 35(3). 387–401. 4 indexed citations
2.
3.
4.
Saeki, Hidehisa, Masashi Akiyama, Masatoshi Abe, et al.. (2023). English version of Japanese guidance for biologics in treating atopic dermatitis. The Journal of Dermatology. 50(10). e311–e322. 6 indexed citations
5.
Kameda, Hideto, et al.. (2023). Cartilage evaluation by ultrasonography in patients with rheumatoid arthritis: a scoping review. Inflammation and Regeneration. 43(1). 34–34.
6.
Baraliakos, Xenofon, Désirée van der Heijde, Joachim Sieper, et al.. (2023). Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study. Arthritis Research & Therapy. 25(1). 172–172. 12 indexed citations
7.
8.
Heijde, Désirée van der, Xenofon Baraliakos, Joachim Sieper, et al.. (2022). Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Annals of the Rheumatic Diseases. 81(11). 1515–1523. 79 indexed citations
9.
10.
Kameda, Hideto, et al.. (2021). Regulation of T cell differentiation by the AP-1 transcription factor JunB. Immunological Medicine. 44(3). 197–203. 39 indexed citations
11.
Coates, Laura C., Sreekumar Pillai, Hasan Tahir, et al.. (2021). Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double‐Blind Withdrawal Study. Arthritis & Rheumatology. 73(9). 1663–1672. 16 indexed citations
12.
Burmester, Gerd R, Vivian P. Bykerk, Maya H Buch, et al.. (2021). Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis. Lara D. Veeken. 61(6). 2596–2602. 6 indexed citations
13.
Combe, Bernard, Proton Rahman, Hideto Kameda, et al.. (2020). Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Research & Therapy. 22(1). 14–14. 34 indexed citations
14.
Tanaka, Yoshiya, Yoshinori Takahashi, Owen Hagino, et al.. (2019). Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Research & Therapy. 21(1). 79–79. 31 indexed citations
15.
Baba, Akira, et al.. (2017). Giant cell arteritis with polymyalgia rheumatica on FDG ‐ PET / CT. Clinical Case Reports. 5(7). 1186–1187. 2 indexed citations
16.
Kameda, Hideto. (2016). [TNF inhibitors].. PubMed. 74(6). 957–62. 1 indexed citations
17.
Izumi, Keisuke, Yuko Kaneko, Hidekata Yasuoka, et al.. (2012). AB0544 Efficacy and safety of tocilizumab in patients with rheumatoid arthritis in the presence or absence of previous treatment with biologics and concomitant treatment with methotrexate. Annals of the Rheumatic Diseases. 71. 669–669. 1 indexed citations
18.
Kaneko, Yuko, Masataka Kuwana, Hideto Kameda, & Tsutomu Takeuchi. (2011). Sensitivity and specificity of 2010 rheumatoid arthritis classification criteria. Lara D. Veeken. 50(7). 1268–1274. 57 indexed citations
19.
Kameda, Hideto, Hayato Nagasawa, Hiroe Ogawa, et al.. (2005). Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis.. PubMed. 32(9). 1719–26. 178 indexed citations
20.
Akama, Hideto, Hirofumi Tanaka, T. Yoshida, Hideto Kameda, & Shinichi Kawai. (1994). GLUCOCORTICOID‐UNRESPONSIVE FEVER IN A PATIENT WITH WEBER‐CHRISTIAN DISEASE. International Journal of Clinical Practice. 48(3). 161–162. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raimón Sanmartí Breakdown of academic impact, for papers by Xavier Le Loët Breakdown of academic impact, for papers by Elliot Chartash Breakdown of academic impact, for papers by Andrea Rubbert‐Roth Breakdown of academic impact, for papers by A. Mékinian Breakdown of academic impact, for papers by Pierre Geborek Breakdown of academic impact, for papers by Alejandro Balsa Breakdown of academic impact, for papers by Olivier Vittecoq Breakdown of academic impact, for papers by Eva Baecklund Breakdown of academic impact, for papers by Emilio Martín Mola
Rankless by CCL
2026